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Gestational trophoblastic disease (GTD) is an aberration of the
trophoblast consisting of a wide spectrum of diseases ranging from
benign hydatidiform mole to highly malignant choriocarcinoma
and placental site trophoblastic tumour. The UK Trophoblastic
Disease Registration Scheme was initiated in 1973 by the Royal
College of Obstetricians and Gynaecologists. There are three
supra-regional centres in the UK: in London (Charing Cross
Hospital), in Sheffield (Weston Park Hospital), and in Dundee
(Ninewells Hospital). The Sheffield team treats by chemotherapy
approximately 5% of all patients registered with this centre – a
lower proportion than in other treatment centres worldwide. This
figure was achieved by adopting stringent treatment criteria and
definitions of persistent trophoblastic disease (PTD).
It has been suggested that such a treatment policy can result in
delayed initiation of chemotherapy in a small subgroup of patients
and that patients who present late may have a poorer prognosis.
This study evaluates the characteristics and outcome of patients
whose chemotherapy was initiated more than 24 weeks after initial
diagnosis as part of a predetermined policy on the part of the
Centre.
MATERIALS AND METHODS
Patients with GTD are registered after diagnosis at the
Trophoblastic Disease Screening and Treatment Centre. They are
then placed on a surveillance programme which mainly consists of
serial measurements of the tumour marker, human chorionic
gonadotrophin (hCG). At our Centre we generally recommend that
patients have a repeat evacuation when the tumour marker remains
elevated or fails to fall in an optimal manner. In addition, the refer-
ring gynaecologist may perform a repeat evacuation if the patient
has persistent symptoms.
Patients who have evidence of PTD as determined by the
criteria for treatment (Table 1) are admitted for assessment and
chemotherapy. The patient is assigned to a risk group (Sheridan et
al, 1993) based on the Charing Cross Prognostic Scoring System
(Bagshawe, 1976). Patients with low risk (score ≤ 7) receive low-
dose methotrexate as the first-line chemotherapy (methotrexate
50 mg intramuscular (i.m.) on alternate days with four doses per
cycle, folinic acid 7.5 mg orally 24 h after each injection and
7-day rest periods between cycles). Those who have an inadequate
tumour response to first-line therapy are transferred to the EA
salvage regimen (etoposide 100 mg m–2 intravenously (i.v.) and
actinomycin D 0.5 mg i.v. daily for 3 days with rest period of
7 days between each cycle). Patients with high-risk disease (risk
score > 7) are treated with the MAE regimen as first-line
chemotherapy (methotrexate 100 mg m–2 i.v. over an hour
followed by a 12 h infusion of 200 mg m–2 is added to and
alternates with the EA regimen).
The computer database at the Centre was searched to identify
patients treated for PTD between 1986 and 1996. The time interval
from diagnosis to start of chemotherapy was calculated for each
patient. Hospital records were reviewed when the interval was
24 weeks or greater to determine patient characteristics, treatment
and outcome.
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A total of 4257 women with gestational trophoblastic disease were
registered in Sheffield between 1986 and 1996. In total, 231 of
these women required chemotherapy for PTD or choriocarcinoma.
Twenty-eight patients were treated ‘late’, with chemotherapy
commencing 24 weeks or more following initial diagnosis. In five
cases this was due to late recurrence of GTD; in five cases there
was delayed referral to the Centre or defaulting follow-up on the
part of the patient. Thus, 18 patients fulfilled the criteria for our
watch and wait policy (i.e. to treat persistent bhCG elevation
6 months post-uterine evacuation).
The median patient age of these 18 patients was 30 years (range
21–57 years). Sixteen patients had suction curettage as initial
mode of evacuation (one was medically induced) and the other
two patients spontaneously miscarried their molar pregnancies. On
histological analysis, 14 had complete hydatidiform moles, three
had partial moles, one had an unclassified mole.
Consistent with previous Unit policy most patients had repeat
uterine evacuations prior to initiation of chemotherapy. All repeat
evacuations were performed by dilatation and curettage. Fourteen
of 18 patients had one repeat evacuation and a further 4/18 patients
had two repeat procedures. Repeat evacuation(s) was performed
in seven cases for continued vaginal bleeding and in 11 for a
persistent or rising hCG levels.
bhCG levels at registration (ranging from 2 to 6 weeks post-
diagnosis) were 66–72 000 (mean 11 300) iu/l. At commencement
of chemotherapy the range was 63–3300 (mean 950) iu/l.
Chemotherapy was commenced at a median of 33 weeks (range
24–56 weeks) after the initial evacuation. Charing Cross Hospital
prognostic scores ranged from 3 to 6, with a median of 4. All
patients had low-risk disease (risk score of ≤ 7); all were started on
single-agent methotrexate, one required salvage therapy with the
EA regimen. All 18 patients are in complete remission. All
patients tolerated chemotherapy well and with minimal clinically
significant side-effects.
During the period of the study, 17 patients were observed for
24 weeks or longer (range 24–44, mean 30) and did not require
chemotherapy because the bhCG level fell spontaneously to
normal. In this group repeat evacuations were done in 10/17
patients (in one case two re-evacuations were performed) – in six
cases for elevated bhCG levels, in four for persistent vaginal
bleeding. bhCG levels at registration were 100–20 000 (mean
5700) iu/l.
DISCUSSION
At the Sheffield Trophoblastic Disease Centre we are able to
successfully adopt stringent treatment criteria for PTD for three
reasons:
1. trophoblastic tumours are generally exquisitely chemosensitive
2. hCG measurements accurately reflect the tumour burden
3. excellent patient compliance with an inclusive national
surveillance scheme.
The chemotherapy policy (Table 1), including the use of repeat
uterine evacuation – which leads to disease resolution in up to
three-quarters of patients in whom this is performed, has enabled
us to expose only 5% of patients registered in our centre to cyto-
toxic chemotherapy, whilst reporting very high overall cure rates
(Sheridan et al, 1993; Hancock, 1997). In the USA, the mobility of
the population and medico-legal factors result in less stringent
criteria being used – women with bhCG not regressing 
to normal in 4–6 weeks receive chemotherapy. This results in
20–30% of all patients receiving cytotoxic agents (Goldstein and
Berkowitz, 1982; Lurain et al, 1983). We conducted this study to
assess whether adopting a stringent policy resulted in increased
morbidity and mortality amongst those who fulfilled our treatment
criteria 6 months or more after initial diagnosis.
Overall, 20% of low-risk disease patients initially treated with
single-agent methotrexate chemotherapy develop resistance, but in
our experience all such patients can be cured with salvage
chemotherapy (Sheridan et al, 1993). In this series all patients had
low-risk disease and all achieved complete remission. One patient
who developed drug resistance was cured with combination
chemotherapy (etoposide/dactinomycin). In the period between
1986 and 1996, the Centre had five deaths out of 231 patients
patients treated with chemotherapy for PTD. It would seem
therefore that mortality is not increased in the ‘late’ treated group.
If mortality is not affected, is there any evidence that this patient
group suffers from increased morbidity? All patients were
assessed as low risk; in addition there was no evidence that more
chemotherapy was required to induce and maintain remission. No
patient had serious drug-associated toxicity. It is, therefore,
concluded that there was no increased morbidity in the late treated
group.
An observation of note in this patient group is the number of
patients with partial hydatidiform moles. It is known that partial
moles rarely develop into PTD (Berkowitz and Goldstein, 1997).
In this series of 18 cases, three histologically confirmed partial
moles were documented. These three cases represent one-third of
all partial moles requiring chemotherapy at our Centre between
during the period of study. It could be argued that our surveillance
programme allows the monitoring of the natural history of a partial
mole; that these tumours have a more indolent course than other
forms of GTD and that patients with such tumours can safely be
monitored for prolonged periods rather than rapidly initiating
chemotherapy.
The more stringent the treatment criteria adopted for
chemotherapy of PTD the smaller the proportion of patients who
will require treatment. This is important as it has been shown that,
whilst chemotherapy regimens are highly efficacious, even the
least toxic regimens used can be associated with significant side-
effects (Gillespie et al, 1997; Sharma et al, 1999) and the more
rigorous regimens can be associated with long-term sequelae
(Rustin et al, 1987, 1996). A stringent treatment policy does mean
that definitive chemotherapy will be delayed in some patients. Our
current treatment policy dictates that chemotherapy is required for
those patients with persistently elevated bhCG 6 months after
initial diagnosis. However, even in this group we are sometimes
justified in adopting a ‘watch and wait’ strategy as during the time
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Table 1 Criteria for chemotherapy in gestational trophoblastic disease at
the Sheffield Trophoblastic Screening Centre
• hCG levels > 20 000 IU/l after 2nd or 3rd evacuation
• Static or rising hCG levels after 2nd or 3rd evacuation
• Persistent uterine haemorrhage with elevated hCG level
• Persistent hCG elevation, 6 months after evacuation
• Pulmonary metastasis with static or rising hCG levels
• Metastasis in liver, brain or gastrointestinal tract
• Histological diagnosis of true choriocarcinomaperiod of this study 17 patients were observed closely for 24 weeks
or longer and did not require chemotherapy, their persistent
trophoblastic disease eventually resolving spontaneously. This
explains the range of intervals to treatment in those patients
requiring chemotherapy.
The study indicates that there is no increased morbidity or
mortality in patients monitored closely for 6 months or more
before initiation of chemotherapy. We conclude that such a
strategy can be safely adopted in the management of PTD where
effective surveillance procedures are available.
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